Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - cefuroxime axetil -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - cefuroxime axetil -

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - cefuroxime sodium 1.6 g equivalent to cefuroxime 1.5 g;   - powder for injection - 1.5 g - active: cefuroxime sodium 1.6 g equivalent to cefuroxime 1.5 g   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1). indications include - respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septi

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - cefuroxime sodium 802mg equivalent to cefuroxime 750 mg;   - powder for injection - 750 mg - active: cefuroxime sodium 802mg equivalent to cefuroxime 750 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1). indications include - respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septi

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 300.72 mg (equivalent: cefuroxime, qty 250 mg) - tablet, film coated - excipient ingredients: propylene glycol; microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; hypromellose; methyl hydroxybenzoate; colloidal anhydrous silica; propyl hydroxybenzoate; sodium lauryl sulfate; titanium dioxide; purified water; sodium benzoate; industrial methylated spirit - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria. . acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. . acute exacerbations of chronic bronchitis, or acute bronchitis. . skin and skin structure infections, for example, furunculosis, pyoderma and impetigo. . acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 150.36 mg (equivalent: cefuroxime, qty 125 mg) - tablet, film coated - excipient ingredients: propylene glycol; sodium lauryl sulfate; croscarmellose sodium; propyl hydroxybenzoate; methyl hydroxybenzoate; hypromellose; microcrystalline cellulose; hydrogenated vegetable oil; colloidal anhydrous silica; titanium dioxide; purified water; sodium benzoate; industrial methylated spirit - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria. . acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. . acute exacerbations of chronic bronchitis, or acute bronchitis. . skin and skin structure infections, for example, furunculosis, pyoderma and impetigo. . acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the tr

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime;   - powder for injection - 1.5 g - active: cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 263mg equivalent to 250 mg cefuroxime;   - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to 250 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.